[1] Riazi K, Azhari H, Charette J H, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2022,7(9):851-861.
[2] Lou T W, Yang R X, Fan J G. The global burden of fatty liver disease: the major impact of China[J]. Hepatobiliary Surg Nutr,2024,13(1):119-123.
[3] Zeng J, Qin L, Jin Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: a community-based study[J]. Hepatobiliary Pancreat Dis Int,2022,21(2):154-161.
[4] Abdelhameed F, Kite C, Lagojda L, et al. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD[J]. Curr Obes Rep,2024,13(3):510-531.
[5] Rinella M E, Neuschwander-Tetri B A, Siddiqui M S, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology,2023,77(5):1797-1835.
[6] Angulo P, Hui J M, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD[J]. Hepatology,2007,45(4):846-854.
[7] Kjaergaard M, Lindvig K P, Thorhauge K H, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease[J]. J Hepatol,2023,79(2):277-286.
[8] Dabbah S, Ben Yakov G, Kaufmann M I, et al. Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients[J]. Minerva Gastroenterol (Torino),2024,70(3):322-331.
[9] McPherson S, Stewart S F, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J]. Gut,2010,59(9):1265-1269.
[10] Xiao G, Zhu S, Xiao X, Yan L, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis[J]. Hepatology,2017,66(5):1486-1501.
[11] Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, et al. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study[J]. Metabolism,2023,147:155666.
[12] Park H, Yoon E L, Kim M, et al. Diagnostic performance of the fibrosis-4 index and the NAFLD fibrosis score for screening at-risk individuals in a health check-up setting[J]. Hepatol Commun,2023,7(10):e0249.
[13] Zhang F, Han Y, Mao Y, et al. Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study[J].Ann Med,2024,56(1):2337739.
[14] Li G, Zhang X, Lin H, et al. Non-invasive tests of non-alcoholic fatty liver disease[J]. Chin Med J (Engl),2022,135(5):532-546.
[15] Zhang X, Zheng M H, Liu D, et al. A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis[J]. Cell Metab,2025,37(1):59-68.e3.
[16] Ye J, Lai J, Luo L, et al. Cytokeratin 18 fragment in liver inflammation and fibrosis: Systematic review and meta-analysis[J]. Clin Chim Acta,2025,569:120147.
[17] Zhang H, Rios R S, Boursier J, et al. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study[J]. Chin Med J (Engl),2023,136(3):341-350.
[18] Armandi A, Rosso C, Younes R, et al. Cross-sectional and longitudinal performance of non-invasive tests of liver fibrosis in patients with non-alcoholic fatty liver disease[J]. J Clin Med,2023,12(2):650.
[19] Liu M, Qiu H, Zhang W, et al. Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol,2023,38(7):1018-1027.
[20] Hegmar H, Wiggers T, Nasr P, et al. Performance of novel collagen turnover biomarkers to detect increased liver stiffness in MASLD[J]. J Intern Med,2024,296(2):177-186.
[21] Li Y, Li C, Zhang L, et al. Serum CHI3L1 as a diagnostic marker and risk factor for liver fibrosis in HBeAg-negative chronic hepatitis B[J]. Am J Transl Res,2022,14(6):4090-4096.
[22] 袁明星,渠东杰,马艳琳,等. 肝脏剪切波弹性成像联合FIB-4指数、血清GP73、CHI3L1对慢性乙型肝炎患者肝纤维化的诊断价值[J]. 现代生物医学进展,2024,24(16):3046-3050.
[23] Eslam M, Fan J G, Yu M L, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease[J]. Hepatol Int,2025,19(2):261-301.
[24] Hu R, Wu B, Wang C, et al. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population[J]. Int J Surg,2024,110(4):2044-2054.
[25] Liguori A, Esposto G, Ainora M E, et al. Liver elastography for liver fibrosis stratification: a comparison of three techniques in a biopsy-controlled MASLD cohort[J]. Biomedicines,2025,13(1):138.
[26] 中国研究型医院学会感染与炎症放射学专业委员会,中华医学会放射学分会传染病学组,中国科技产业化促进会数字健康专业委员会,等. 慢性乙型肝炎肝纤维化MRI诊断专家共识(2023年版)[J]. 中华肝脏病杂志,2023,31(10):1009-1017.
[27] Liang J X, Ampuero J, Niu H, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography[J]. J Hepatol,2023,79(3):592-604.
[28] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志,2024,32(5):418-434.
[29] 任浩,徐辉,杨大为,等. 磁共振弹性成像评估非酒精性脂肪性肝病肝纤维化程度[J]. 中国医学影像学杂志,2022,30(2):106-110.
[30] 徐蕊,何明钰,刘新峰,等. 磁共振新兴技术在肝纤维化的研究进展[J]. 实用医学杂志,2023,39(1):124-128.
[31] Newsome P N, Sasso M, Deeks J J, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study[J].Lancet Gastroenterol Hepatol,2020,5(4):362-373.
[32] Ravaioli F, Dajti E, Mantovani A, et al. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis[J]. Gut,2023,72(7):1399-1409.
[33] Taru M G, Tefas C, Neamti L, et al. FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin[J]. PLoS One,2024,19(5):e0303971.
[34] Noureddin M, Truong E, Gornbein J A, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis[J]. J Hepatol,2022,76(4):781-787.
[35] Imajo K, Saigusa Y, Kobayashi T, et al. M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis[J]. Hepatol Res,2023,53(9):844-856.
[36] Kim B K, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD[J]. J Hepatol,2022,77(6):1482-1490.
[37] Dalbeni A, Lombardi R, Henrique M, et al. Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis[J]. Hepatology,2024,79(5):1107-1116.
[38] Sanyal A J, Foucquier J, Younossi Z M, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores[J]. J Hepatol,2023,78(2):247-259.
[39] Papatheodoridi M, De Ledinghen V, Lupsor-Platon M, et al. Agile scores in MASLD and ALD: external validation and their utility in clinical algorithms[J]. J Hepatol,2024,81(4):590-599. |
